SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER

cancers are categorized as small cell lung cancer, a subtype with a neuroendocrine phenotype, or non-small cell lung cancer, which comprises adenocarcinoma, squamous cell

The objective of the present study was to analyze the effect of chemotherapy on the physical condition of patients with advanced non-small cell lung cancer

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern

(2015) Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.

The objective of the present study was to analyze the effect of chemotherapy on the physical condition of patients with advanced non-small cell lung cancer

Efficacy and safety of amrubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy. Further investigations

cancers are categorized as small cell lung cancer, a subtype with a neuroendocrine phenotype, or non-small cell lung cancer, which comprises adenocarcinoma, squamous cell